Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombasthenia

Single-arm design with a 24-week run-in followed by 48 weeks of treatment; primary endpoint is annualized treated bleed rate

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (NASDAQ:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating sutacimig (HMB-001) as a potential prophylactic treatment for people with Glanzmann thrombasthenia (GT). The first participants have been consented and are scheduled to enter the trial's run-in period in the fourth quarter of 2026. GT is a serious, inherited platelet function disorder for which no prophylactic therapy is currently approved. Sutacimig is an investigational, once-weekly subcutaneous bispecific antibody designed to help form stable hemostatic plugs at the site of bleeding, compensating for platelet dysfunction.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.